Neuphoria Therapeutics Inc. Common Stock (NEUP)

• Market cap: $11.1B
• 1 day: 4.65%
• 5 days: 1.61%
• 1 month: 7.51%
• 3 months: 7.51%
• 6 months: 7.51%
• Year to date: 7.51%
• 1 year: 7.51%
• 5 years: 7.51%
• 10 years: 7.51%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.

Employees: 24

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

31% less funds holding

Funds holding: 13 [Q2] → 9 (-4) [Q3]

37% less capital invested

Capital invested by funds: $1.74M [Q2] → $1.1M (-$640K) [Q3]

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6